MedTrace Logo

Role of A Disintegrin and Metalloproteinase (ADAM) in Epithelial Dysfunction

NCT00898859 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2015-01-16

No results posted yet for this study

Summary

Despite emerging implications for ADAMs (and matrix metalloproteinases (MMPs)) in disease progression, the mechanisms that lead to activation of specific ADAMs (and MMPs) and their actions in chronic obstructive pulmonary disease (COPD) are still incompletely understood. In the current study, the researchers aim to investigate the effects of cigarette smoke on cellular parameters that are relevant for development of COPD and the involvement of ADAM activity in these effects. By studying the effects of ADAM inhibition, the researchers aim to provide novel insights in the role of ADAMs in the development of COPD, which may offer new therapeutic targets for the treatment of COPD.

Conditions

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Maarten van den Berge, PhD · University Medical Center Groningen

  • maarrten van den Berge, PhD · University Medical Center Groningen

  • Irene Heijink, PhD · University Medical Center Groningen

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-05-31
Completion
2012-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00898859 on ClinicalTrials.gov